Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

A roundup of the first quarter's key oncology drug approvals and rejections.

The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.

Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.

Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.

Of the big oncology deals since 2016, there are still plenty that could go either way.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Lifileucel heads up the list of upcoming US FDA catalysts.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.